10-K: Yijia Group Reports Soaring Revenue and Profit Driven by Healthcare Segment Growth Amidst Internal Control Concerns

Yijia Group Corp. announced significantly increased revenues and net income for fiscal year 2025, primarily fueled by the rapid expansion of its healthcare products segment, despite ongoing internal control deficiencies.

Summary

• Revenue increased 366% to $2,662,105 in fiscal year 2025 from $570,694 in fiscal year 2024.
• Net income rose to $850,746 in fiscal year 2025 from $140,865 in fiscal year 2024.
• Gross profit increased 309% to $1,575,710 in fiscal year 2025 from $377,711 in fiscal year 2024.
• The healthcare segment drove growth, with sales of healthcare products reaching $2,651,267 in fiscal year 2025, up from $544,594 in fiscal year 2024.
• Consulting service income decreased to $10,838 in fiscal year 2025 from $26,100 in fiscal year 2024.
• Cash balance increased to $782,810 as of April 30, 2025, from $593,036 in the prior year.
• Accounts receivable saw a substantial increase to $1,266,951 in fiscal year 2025 from $0 in fiscal year 2024.
• The company has significant customer concentration, with three customers accounting for 91% of total net revenues in fiscal year 2025.
• Internal controls over financial reporting were deemed ineffective due to material weaknesses, including the absence of an Audit Committee, inadequate cash controls, and insufficient information technology controls.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial growth in revenue and net income, driven by its healthcare segment. However, significant concerns remain regarding internal control deficiencies, high customer/vendor concentration, and lack of insurance, which temper the overall positive financial performance.

Positives

• Significant revenue growth of 366% year-over-year, primarily from the healthcare products segment.
• Substantial increase in net income by 504% year-over-year.
• Improved cash position, with cash increasing to $782,810.
• Positive shift in cash flow from operating activities, moving from a net cash used of $375,880 in fiscal year 2024 to a net cash generated of $192,774 in fiscal year 2025.
• Gross profit margin improved, indicating efficient cost management relative to sales growth in the healthcare segment.

Negatives

• Consulting service income significantly decreased by 58.4% year-over-year.
• Personnel and benefit costs increased by 222%, and general and administrative expenses increased by 82%, impacting profitability.
• Significant increase in accounts receivable to $1,266,951, indicating potential cash flow issues if not collected efficiently.
• High customer concentration, with 91% of fiscal year 2025 revenue from three customers, posing a significant business risk.
• High vendor concentration, with 86% of fiscal year 2025 purchases from one vendor.
• No insurance coverage, which could lead to cessation of operations if litigation occurs.
• No research and development costs incurred, potentially limiting future product innovation.

Risks

• Absence of insurance coverage, potentially leading to cessation of operations if litigation arises.
• Lack of formalized cybersecurity measures, dedicated team, or specific protocols, leaving the company vulnerable to cyberattacks and data breaches.
• Thinly traded common stock with no active trading market, affecting liquidity for investors.
• Dependence on key personnel and the need to attract new management.
• Intense market competition requiring continuous product innovation and brand strengthening.
• Reliance on a single market if international expansion is not successful.
• Limited operating history and start-up stage operations, with inherent risks of new business enterprises.
• Possible cost overruns due to price and cost increases in services and products.
• Significant concentration of credit risk in accounts receivable due to major customers.
• High customer concentration (91% of fiscal year 2025 revenue from three customers).
• High vendor concentration (86% of fiscal year 2025 purchases from one vendor).
• Material weaknesses in internal control over financial reporting, including no Audit Committee, inadequate cash controls, and insufficient information technology controls, increasing the risk of material misstatement.
• No written code of business conduct and ethics.
• No insider trading policies and procedures.

Future Outlook

The company continues to seek opportunities to increase profits in fiscal year 2025. Forward-looking statements are subject to risks including technological advances, impact of competition, dependence on key personnel, effectiveness of cost and marketing efforts, acceptances of products, ability to expand markets, and the availability of capital or other funding on satisfactory terms.

Management Comments

• We currently have people ready to fill positions as soon as they are needed in both office staff and work force roles.
• We do not believe that government regulations have a material impact on the way we conduct our business.
• We are in the process of evaluating our cybersecurity needs and developing appropriate measures to enhance our cybersecurity posture.
• Our goal is to establish a cybersecurity framework that is commensurate with our size, complexity and the nature of our operations, thereby reducing our exposure to cybersecurity risks.
• We plan to retain future earnings, if any, for use in our business.
• We continue to look for other opportunities which could potentially increase the profits of the Company in the year 2025.
• While not being legally obligated to have an audit committee, it is the managements view that such a committee, including a financial expert member, is an utmost important entity level control over the Companys financial statement.
• Based on the fact that our current business affairs are simple, any such committees are excessive and beyond the scope of our business and needs.

Industry Context

The company operates in the healthcare products and business consulting sectors. Its focus on anti-aging products (NAD+ boosters) aligns with a growing global trend in wellness and longevity. The significant revenue growth in healthcare products suggests strong market demand for such offerings, potentially outperforming the consulting segment. The lack of R&D and reliance on a single product type (NAD+ boosters) could be a competitive disadvantage in a rapidly evolving health and wellness market.

Comparison to Industry Standards

• The company's rapid revenue growth (366%) in the healthcare segment is exceptionally high, potentially indicating strong initial market penetration for its anti-aging products, likely exceeding industry averages for established healthcare product companies.
• The absence of R&D expenses is unusual for a company in the healthcare product space, especially one focused on 'anti-aging' products, where innovation and clinical validation are often key competitive differentiators. Comparable companies like Elysium Health (Basis) or ChromaDex (Tru Niagen), which also focus on NAD+ precursors, typically invest heavily in scientific research and clinical trials to support product claims and differentiate themselves.
• The high customer concentration (91% from three customers) and vendor concentration (86% from one vendor) are significantly higher than industry best practices for diversified businesses, which typically aim for no single customer or vendor to account for more than 10-20% of revenue/purchases to mitigate risk.
• The reported material weaknesses in internal controls, particularly the lack of an independent Audit Committee, inadequate cash controls, and insufficient IT controls, fall significantly below the corporate governance and financial reporting standards expected of publicly traded companies, even smaller reporting companies. Larger, more mature companies like Johnson & Johnson or Pfizer have robust internal control frameworks and independent audit committees.

Management Changes

Corporate Governance

Legal Proceedings

• No material, existing or pending legal proceedings against the company.

Related Party Transactions

• Repayment of $3,000 to related parties (specifically Qiuping Lu) in fiscal year 2025.
• Share-based compensation of $2,000 recognized in fiscal year 2025 and $1,000 in fiscal year 2024 for Steve Niu, with 60,000 common stocks to be issued.
• Proceeds from private offering in fiscal year 2024 included $60,000 from Qiuping Lu and $110,060 from Ruiming Zhou.
• Professional fees of $1,450 paid to Triangle Accounting Inc. (an entity controlled by Steve Niu) in fiscal year 2024.
• Free office space provided by a stockholder, with the cost deemed nominal and not recognized.

Stakeholder Impact

• Shareholders: Positive financial results (revenue, net income growth) could be beneficial, but significant corporate governance and internal control deficiencies, along with high concentration risks, pose substantial long-term concerns. The thinly traded stock and lack of dividends also impact shareholder value.
• Employees: The company has only one full-time employee besides officers, indicating a very lean operation. Increased personnel costs suggest higher compensation for key management.
• Customers: High customer concentration means the loss of a few major customers could severely impact revenue. The focus on anti-aging products and health consultation services aims to meet customer needs in a growing market.
• Suppliers: High vendor concentration means reliance on a single major supplier, which could pose supply chain risks if that relationship is disrupted.
• Creditors: Improved cash flow from operations and increased cash balance are positive for creditors, but the lack of insurance and internal control weaknesses could be concerns.

Next Steps

• Evaluate cybersecurity needs and develop appropriate measures to enhance cybersecurity posture.
• Consider engaging external cybersecurity experts to advise on best practices, conducting vulnerability assessments, and developing an incident response strategy.
• Board to oversee any cybersecurity risk management framework and a dedicated committee or officer appointed by the Board will review and approve any cybersecurity policies, strategies and risk management practices.
• Establish an Audit Committee, Compensation Committee, and Nominations and Corporate Governance Committee.
• Appoint an Audit Committee financial expert.
• Implement appropriate cash controls, including segregation of duties and dual signatures on bank accounts.
• Implement appropriate information technology controls, including formal data backup procedures and off-site storage.
• Adopt a written code of business conduct and ethics.
• Adopt insider trading policies and procedures.
• Continue to look for other opportunities which could potentially increase the profits of the Company.
• Retain future earnings, if any, for use in business, including product development, acquisitions, or expansion.

Key Dates

Recommendation

While Yijia Group Corp. demonstrated impressive revenue and net income growth driven by its healthcare segment, the company faces significant structural and governance challenges. The material weaknesses in internal controls, high customer and vendor concentration, and lack of insurance coverage introduce substantial operational and financial risks. The stock is thinly traded, limiting liquidity. Given the strong top-line growth but severe underlying risks, a 'hold' recommendation is appropriate for investors who are already exposed, suggesting they monitor the company's progress in addressing its governance and control deficiencies before considering further investment. For new investors, the risks currently outweigh the potential rewards.

Keywords

Healthcare products, anti-aging, NAD+, consulting services, financial services, SEC filing, 10-K, YIJIA GROUP CORP, YJGJ, Nutripeak Trading Corporation, corporate governance, internal controls, financial performance, revenue growth, net income, market concentration